A key element in Cortendo Invest AB’s business and R&D strategy is to enter into collaborative agreements with companies that can offer the best and most appropriate competencies to support the drug development process. Key relationships include:

Camurus AB for drug formulation work

Covance Ltd for the clinical development programme and regulatory submissions

Penn Pharmaceuticals Ltd for the manufacturing of CORT001 capsules for use in clinical trials.